Terns Pharmaceuticals Inc. held its 2025 Annual Meeting of Stockholders on June 11, 2025. Stockholders voted on two proposals during the meeting. The election of three Class I directors, Robert Azelby, Hongbo Lu, and Heather Turner, was approved. Additionally, the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.